Meeting
2022 ASCO Genitourinary Cancers Symposium
Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
Authors
Grant Rauterkus
Tulane Cancer Center, New Orleans, LA
Grant Rauterkus , Agreen Hadadi , Reagan Barnett , Caroline Weipert , Leylah Drusbosky , Xin Gao , Michael B. Lilly , Alan Haruo Bryce , Syed Arsalan Ahmed Naqvi , Pedro C. Barata , Mehmet Asim Bilen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 165)
DOI
10.1200/JCO.2022.40.6_suppl.165
Abstract #
165
Poster Bd #
J6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Microsatellite instability in prostate cancer and response to immune checkpoint blockade.
First Author: Wassim Abida
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial.
First Author: Yoshiaki Nakamura
Poster
2023 ASCO Genitourinary Cancers Symposium
Characterizing changes in tumor mutational burden (TMB) by serial circulating tumor DNA (ctDNA) testing in patients with advanced prostate cancer (aPC).
First Author: Daniel S Childs
Poster
2022 ASCO Annual Meeting
Clinical outcomes of immune checkpoint inhibitor (ICI) therapy among Veterans Affairs patients with colorectal cancer and discordant dMMR/MSI-H status.
First Author: James Isaacs